TomoTherapy
TomoTherapy is a radiation therapy technology brand that developed helical, CT-scanner-based radiotherapy systems for cancer treatment. Acquired by Accuray in 2010, it now operates as the Radixact product line, sold as capital equipment to hospitals and cancer treatment centers.
- Company typePublic
- Founded1997
- HeadquartersMadison, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What TomoTherapy does
TomoTherapy is a medical radiation therapy technology brand originally founded in 1997 and headquartered in Madison, Wisconsin. The company developed and commercialized helical radiation therapy systems for cancer treatment, building on a unique architecture in which the radiation delivery system is constructed on a CT scanner foundation. This allows daily CT-based imaging to guide treatment each day and enables a 360-degree helical radiation dose delivery around the patient, with the stated clinical benefit of high tumor dose conformity and reduced dose to surrounding healthy tissue across a broad range of cancer types, including breast, head and neck, lung, prostate, brain, cervical, esophageal, rectal, anal, and gynecological cancers. TomoTherapy was acquired by Accuray Incorporated (NASDAQ: ARAY) in 2010 and ceased to exist as a standalone legal entity; its technology platform is now sold by Accuray under the Radixact System brand.
The Radixact System is sold as capital equipment directly to cancer treatment centers and hospitals through an enterprise field sales motion, with global reach indicated by a Treatment Centers locator and worldwide distribution channels. The revenue model is one-time capital equipment sale to healthcare facilities rather than subscription or per-treatment licensing, with pricing not publicly disclosed and negotiated on a quote basis. Customer acquisition is supported by a content-and-testimonial marketing program emphasizing patient stories, clinical evidence (cited as 20 years for TomoTherapy/Radixact and 30 years for the broader technology), educational resources, and a presence at healthcare-provider events. The named leaders Frederick A. Robertson (CEO) and Stephen C. Hathaway (CFO) appear to be associated with the parent Accuray rather than an independent TomoTherapy entity. Earlier in its standalone history, TomoTherapy raised a $3 million round in 1999 led by Clarevia Ventures with Avalon Ventures, a subsequent round from Advantage Capital in 2000, and listed on NASDAQ as TTPY before being acquired and subsequently delisted.
TomoTherapy firmographics
Firmographics- Name
- TomoTherapy
- Legal name
- Accuray Incorporated
- Website
- https://tomotherapy.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- TomoTherapy is a radiation therapy technology brand that developed helical, CT-scanner-based radiotherapy systems for cancer treatment. Acquired by Accuray in 2010, it now operates as the Radixact product line, sold as capital equipment to hospitals and cancer treatment centers.
- Ownership category
- akta.pro rank
TomoTherapy industry classification
Industry- Product category
- Radiation Therapy Equipment
- NAICS
- Irradiation Apparatus Manufacturing (334517)
- SIC
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
- akta.pro secondary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where TomoTherapy is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TomoTherapy business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Radiotherapy Systems Sales: Sale of sophisticated radiation therapy equipment (TomoTherapy/Radixact systems) to cancer treatment centers and hospitals. The systems are capital equipment purchases for healthcare facilities providing radiation therapy services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
TomoTherapy product offering
Product offeringCore offering
TomoTherapy (now marketed as the Radixact System under Accuray Incorporated) develops and sells a radiation therapy platform built on a CT scanner foundation that uses daily imaging guidance and 360-degree helical delivery to administer precise radiation doses to tumors while sparing healthy tissue. The company sells capital radiotherapy equipment to cancer treatment centers and hospitals worldwide for the treatment of routine to complex tumors, including breast, head and neck, lung, prostate, brain, and gastrointestinal cancers.
Product overview
TomoTherapy is a technology brand owned by Accuray Incorporated. The core product is the Radixact System, which incorporates TomoTherapy technology as its foundational platform. The Radixact System is a radiation therapy platform that combines CT-based imaging with 360-degree helical radiation delivery to treat various cancer types. The system uses daily imaging to guide treatment and deliver precise radiation doses, making it suitable for routine to complex tumors, hard-to-reach areas, and recurrent tumors. TomoTherapy technology represents the core delivery mechanism while Radixact is the branded product name under which this technology is sold.
Differentiator
Problem solved
Functional benefit
Brands
- Radixact: Radiation therapy system utilizing TomoTherapy helical technology for precise cancer treatment delivery from 360 degrees around the patient.
- TomoTherapy
Products and services
- Radixact System
Quantifiable outcome
- High precision minimizes dose to surrounding healthy tissues, significantly reducing common side effects of radiation therapy such as fatigue or skin problems
- +1 more outcomes
Companies that use TomoTherapy
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
TomoTherapy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TomoTherapy partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
TomoTherapy competitors and assessment
Company assessmentEmerging players
- Brainlab: Brainlab provides radiation oncology treatment planning software and image-guided workflows that complement or compete with elements of the Radixact ecosystem, particularly in planning and intra-operative imaging.
- ViewRay: ViewRay pioneered MR-guided radiation therapy (MRIdian), an emerging modality competing for complex and adaptive treatment cases that TomoTherapy also targets with its CT-guided helical system.
- IBA (Ion Beam Applications): IBA is a global leader in proton therapy systems and radiopharma solutions, offering an alternative high-precision modality that competes with TomoTherapy for complex cancer treatment referrals.
- Mevion Medical Systems: Mevion develops compact proton therapy systems (MEVION S250i) positioned as an alternative to photon-based systems like Radixact, particularly for pediatric and complex oncology cases.
Direct peers
- Elekta: Elekta manufactures linear accelerators (Versa HD, Elekta Harmony) and the Leksell Gamma Knife, directly competing with Radixact in the external beam radiation therapy equipment market worldwide.
- Varian Medical Systems (a Siemens Healthineers company): Varian is the dominant manufacturer of linear accelerators (TrueBeam, Edge) and radiation oncology software, competing head-to-head with Radixact in cancer treatment center capital purchases globally.
Broad incumbents
- Accuray Incorporated: Accuray is the parent company that absorbed TomoTherapy in 2010 and now sells both the CyberKnife and Radixact platforms; it is the most direct corporate peer given overlapping radiation therapy product portfolios.
- Siemens Healthineers: Following its acquisition of Varian, Siemens Healthineers offers an integrated diagnostic imaging and radiation therapy portfolio that competes broadly with Accuray/TomoTherapy in hospital oncology procurement.
- Philips: Philips operates in diagnostic imaging, image-guided therapy, and oncology informatics, providing adjacent or competing technologies for hospitals building integrated cancer care pathways that include Radixact systems.
- GE Healthcare: GE Healthcare supplies CT simulators, PET/CT systems, and oncology imaging software that are routinely procured alongside or in place of dedicated radiation therapy systems like Radixact, making it a relevant adjacent competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
TomoTherapy social profiles
Digital presenceTomoTherapy financial estimates
Financial estimateRevenue estimate
Valuation estimate
TomoTherapy leadership team
Management profileNumber of profiles
Profiles2 records
TomoTherapy funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TomoTherapy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TomoTherapy
What does TomoTherapy do?
TomoTherapy (now marketed as the Radixact System under Accuray Incorporated) develops and sells a radiation therapy platform built on a CT scanner foundation that uses daily imaging guidance and 360-degree helical delivery to administer precise radiation doses to tumors while sparing healthy tissue. The company sells capital radiotherapy equipment to cancer treatment centers and hospitals worldwide for the treatment of routine to complex tumors, including breast, head and neck, lung, prostate, brain, and gastrointestinal cancers.
Is TomoTherapy a public or private company?
TomoTherapy is a public company. It is classified as corporate owned and is currently acquired.
When was TomoTherapy founded?
TomoTherapy was founded in 1997. It employs 501 to 1,000 people.
Where is TomoTherapy based?
TomoTherapy is headquartered in Madison, United States, in the North America region.
How does TomoTherapy make money?
One revenue line is on record: radiotherapy Systems Sales.
Who are TomoTherapy's main competitors?
Emerging players on record are Brainlab, ViewRay, IBA (Ion Beam Applications) and Mevion Medical Systems. Direct peers are Elekta and Varian Medical Systems (a Siemens Healthineers company). Broad incumbents are Accuray Incorporated, Siemens Healthineers, Philips and GE Healthcare.
Does TomoTherapy have an API?
No public API is recorded for TomoTherapy.
What industry is TomoTherapy in?
TomoTherapy's product category is Radiation Therapy Equipment. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3844.